[CAS NO. 871361-88-5]  SC66

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [871361-88-5]

Store
Catalog
SLK-S5313
Brand
Selleck
CAS
871361-88-5

DESCRIPTION [871361-88-5]

Overview

MDLMFCD05025493
Molecular Weight276.33
Molecular FormulaC18H16N2O
SMILESO=C1/C(CCC/C1=C\C2=CC=NC=C2)=C/C3=CC=NC=C3

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM3.6189 mL18.0943 mL36.1886 mL
5 mM0.7238 mL3.6189 mL7.2377 mL
10 mM0.3619 mL1.8094 mL3.6189 mL
50 mM0.0724 mL0.3619 mL0.7238 mL

Description

SC66 is an allosteric inhibitor which displays a dual-inhibitory function toward activity with IC50 values of 0.77, 2.85 and 0.47 μg/ml in HepG2, Huh7 and Hep3B cells after 72 h treatment, respectively.

Targets

Akt [1]

In vitro

SC66 reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in HCC cells. SC66 treatment leads to a reduction in total and phospho-AKT levels. This is associated with alterations in cytoskeleton organization, a reduction in expression levels of E-cadherin, β-catenin and phospho-FAK, together with up-regulation of Snail protein levels. In addition, SC66 induces the production of reactive oxygen species (ROS) and DNA damage. SC66 affects AKT/mTOR signaling in HCC cell lines.

In vivo

In the mouse xenograft tumor model of Hep3B cells, SC66 treatment significantly reduces tumor volume to 37% on day 17 of treatment when compared with tumors in the untreated group. The inhibition of cell growth correlates with a reduction in phospho-AKT levels in the tumors of animals treated with SC66.